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Introduction
The successful development of a gene therapy approach to B-cell 
lymphoma requires the construction of vectors that specifically 
target cancer cells and the use of an appropriate model for evalu-
ation of these vectors. Canine lymphoma represents an excellent 
model of human non-Hodgkin lymphoma. The canine disease 
has a similar etiology and presentation to the human disease, 
the model has an intact immune system and the size of the ani-
mal model allows for extrapolation to humans.1,2 Recombinant 
Adenoviral (Ad) vectors derived from human serotypes 2 and 5 
are the most promising vehicles for successful in vivo gene deliv-
ery, based on previously demonstrated efficiency in successful 
gene delivery in a number of cancer gene therapy applications, 
including gastric neoplasms and cancers of the head and neck.3,4 
Recombinant adenovirus vectors (Ad) have been recognized as effective in vivo gene delivery vehicles and utilized as 
gene therapy agents for a number of cancers. The elucidation of viral entry mechanisms has allowed the development of 
recombinant vectors that exploit existing cell surface receptors to achieve entry into the cell. B lymphocytes are normally 
resistant to infection by adenovirus 5, likely due to the lack of the Coxsackie and Adenovirus receptor (CAR). Using reverse-
transcriptase pCR and flow cytometry, the CD40 receptor has been shown to be expressed on many lymphoma cells. We 
exploited this finding to develop a gene therapy strategy for treatment of canine B-cell lymphoma. Ad5 was targeted 
to cells expressing CD40 via CD40 ligand (CD40L) and was effective in infecting CD40-expressing control cells; however, 
both primary canine lymphoma cells and cell lines demonstrated limited evidence of transduction. Following receptor 
binding, adenovirus entry into cells may require interaction with αvβ3/5 integrins; we demonstrate that canine lymphoma 
cells are deficient in these integrins. Reduced αvβ3 integrin expression may render these cells incapable of internalizing 
Ad vectors. Thus, any viral targeting approaches for treatment of canine lymphoma must also take into account the 
potential lack of internalization signals.
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The use of adenoviral vectors for gene transfer has a number of 
benefits: viral stocks can be produced easily and quickly, there 
is robust gene expression with little risk of insertional mutagen-
esis, and infection and subsequent gene expression can occur in 
quiescent cells.5 Potential limitations to the use of recombinant 
adenoviruses as agents for gene therapy include the potential lack 
of transduction of target tissue by Ad vectors due to the paucity of 
native receptors on target cells, and the possibility of transfer to 
normal cells as the native Ad receptor, CAR, is present on a wide 
range of human tissue types.6,7
Entry of Ad into cells is a multi-step process, requiring 
first the binding of the native CAR by the viral fiber knob, 
followed by interaction of an RGD motif in the penton base 




 integrins on the cell surface.8-10 Cells of the 
lymphocyte lineage have proven refractory to Ad infection, 
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Results
Ad target ng to CD40-positive cells. In order to evaluate the effi-
ciency of transduction with adenovirus particles targeting CD40 
with CD40L, 293CD40 cells expressing canine CD40 were cre-
ated. These cells and control parental HEK293 cells were used 
to assess the ability to provide receptor-specific delivery to target 
cells. Transduction by control and CD40 targeted vectors was 
assessed by measuring the luciferase activity in cell lysates fol-
lowing incubation (Fig. 1A). Both HEK293 and 293CD40 cells 
express CAR and were efficiently transduced by untargeted virus 
with luciferase activity increasing in a dose-dependent manner 
(data not shown). While transduction was achieved in both cell 
lines with retargeted virus, the level of transduction in 293CD40 
cells was higher than parental cells with either retargeted vec-
tor. To further demonstrate this transduction was achieved in a 
CAR-independent manner, a recombinant knob protein which 
binds to and blocks CAR was utilized. Incubation of cells with 
recombinant knob blocked transduction of HEK293 cells with 
wild-type (wt) virus, and luciferase activity was reduced to 2% 
of that observed without blocking. By contrast, blocking with 
recombinant knob prior to infection had less effect on 293CD40 
cells. Luciferase activity remained almost unchanged at 94.7% 
for Ad5-ff-hCD40L and 85% for Ad5-ff-cCD40L (Fig. 1B). 
While the reduction in luciferase with the canine CD40L vec-
tor achieved statistical significance, it was far less of an effect 
than was seen in HEK293 cells. This data indicates targeting 
CD40 via CD40L is an effective method of redirecting adenovi-
rus tropism, and that the interaction is specific to CD40 and does 
not involve CAR. Additionally, this data suggests that human 
CD40L may serve as a better ligand for canine CD40 than native 
ligand.
which has been hypothesized to be due to the lack of cell sur-
face expression of the primary Ad receptor CAR.11 Ad vectors 
have been suggested as suitable vectors for transducing lym-
phocytes and CAR-expressing lymphocytes have demonstrated 
efficient transduction by recombinant Ad.12,13 Ad has been used 
in conjunction with a bispecific conjugate to achieve cell entry 
in a CAR-independent fashion in human B lymphocytes via 
CD70;14 murine B lymphocytes activated with lipopolysac-
charide (LPS) were transduced with Ad modified to contain 
a polylysine heparin binding motif in the fiber protein.15 This 
same modification was also successful in transducing human 
myeloma and myeloid leukemia cells in the presence of growth 
factors.16 Therefore, the development of an adenoviral vector 
to target B-cell lymphoma requires the modification of native 
viral tropism either by modification of the viral capsid or by 
the use of a bispecific conjugate that binds a cell surface recep-
tor. To this end, CD40 was recognized as a potential candidate 
molecule for retargeting. The CD40 molecule is expressed on B 
lymphocytes and the interaction between CD40 and its ligand 
promotes growth and differentiation of these cells.17
As a model for B-cell lymphoma targeted therapy, capsid-
modified vectors retargeted to human and canine CD40 and a 
bispecific conjugate comprised of the soluble CAR ectodomain 
(sCAR) and CD40L were utilized. Both human- and canine-
derived cell lines and primary canine lymphoma cells were used 
to evaluate the efficacy of the retargeted vectors in transducing 
cells in a CAR-independent manner. The following report dem-
onstrates the feasibility of retargeting Ad to CD40, and identi-
fies that other cellular components necessary for internalization 
of the vector may be lacking in canine lymphoma. In particular, 




 integrins fail to internalize virus after it is 
bound by the CD40-CD40L interaction.
Figure 1. (A) Transduction of CD40-positive cells by targeted vector. CD40-negative heK293 cells and CD40-positive 293CD40 cells were infected with 
either Ad5-ff-hCD40L or Ad5-ff-cCD40L at MOI of 10, 102 or 103 vp/cell. Transduction was indicated by luciferase activity; this was measured from cell 
lysates and is reported as relative light units. Transduction increased with both vectors in both cell lines in a dose dependent manner; the highest level 
of transduction as indicated by luciferase activity was seen with the Ad5-ff-hCD40L vector. The values were shown as relative infectivity by taking the 
level of luciferase at 10 vp/cell as 100% and expressing other readings as relative percentage increase. (B) Incubation of cells with recombinant knob 
blocked transduction by untargeted virus. Cells were incubated with recombinant knob to block CAR prior to infection with wt virus and luciferase 
activity was used to measure transduction. In CD40-negative cells infected with wt virus, luciferase activity was reduced to 2% while in CD40-positive 
cells infected with targeted virus, there was little reduction in transduction efficiency as determined by luciferase activity. error bars indicate standard 
deviation. *p < 0.05; ***p < 0.001.
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cells were analyzed by flow cytometry and chosen for transduc-
tion experiments on the basis of positive CD21 and CD40 stain-
ing (Fig. 4). Cells isolated from five individual cases of primary 
lymphoma met these criteria and were tested. These cells were 
extracted from lymph nodes following excision and virus was 
added within 24 h of isolation. Cells were infected with control 
untargeted virus, targeted virus (Ad5-ff-hCD40L and Ad5-ff-
cCD40L), and wt virus complexed with sCAR-hCD40L, incu-
bated at 37°C at times ranging from 24–72 h, and then luciferase 
activity was measured. Two of the five cases showed no trans-
duction at any point; however, luciferase activity was detected in 
three cases. In these three cases, the highest level of transduction 
CD40 mediated gene delivery in canine cell lines. 
Following the success of targeting 293CD40 cells with 
modified vectors, demonstration of this process in CD40 
positive canine cell lines was attempted. Initial examina-
tion was performed in DH82, a canine histiocytoma line 
determined to be CD40-positive by RT-PCR.26 These cells 
were poorly infected by CD40 targeted virus. Subsequent 
flow cytometry with anti-CD4  antibody showed these 
cells to be devoid of cell-surface CD40 (data not shown). 
Canine lymphoid lines OSW and 17–71 were then 
obtained for this task. Both lymphoma cell lines were 
shown to be CD40 positive by flow cytometry (Fig. 2). To 
evaluate transduction with the retargeted vectors, OSW 
and 17–71 cells were infected with Ad5, Ad5 ff hCD40L 
and Ad5 ff cCD40L at MOIs ranging from 10–103 virus 
particles per cell and incubated for 24 h. Both lymphoma 
cell lines showed low-level transduction by wt virus at a 
moi of 103 vp/cell indicated by luciferase activity. This was 
approximately 10-fold higher in OSW cells than 17–71 
cells. There was no transduction detected in either cell line 
in response to the retargeted vectors Ad5-ff-hCD40L or 
Ad4-ff-cCD40L. The efficacy of the sCAR-CD40L bipha-
sic adapter in achieving gene transfer via CD40 was also 
evaluated in these cell lines. Adaptor use increased lucifer-
ase expression 3.7-fold in OSW cells. To confirm that the 
increase in luciferase expression was due to the interaction 
of CD40L and CD40 and not via another viral component, the 
sCAR-6His adapter was used as a negative control and luciferase 
activity was reduced below background levels (Fig. 3).
These experiments demonstrated canine lymphoma lines posi-
tive for surface CD40 by flow cytometry were resistant to infection 
by CD40-targeted adenoviruses. Moderate levels of transduction 
were achieved, however, when these cells were infected with wt 
virus and bispecific adapter.
CD40-mediated gene delivery in primary lymphoma cells. 
Following experiments to demonstrate transduction of canine 
cell lines via CD40, we attempted to transduce primary canine 
lymphoma cells with the targeted viruses. Following isolation, 
Figure 2. expression of CD40 by lymphoma cell lines. The canine lymphoma cell lines OsW and 17–71 were analyzed for CD40 expression using anti-
CD40 monoclonal antibody by flow cytometry. Cells were incubated with a primary anti-CD40 monoclonal antibody labeled with Zenon Alexa 610/Rpe.
Figure 3. Use of a bispecific adapter to increase CD40 targeted transduction in 
lymphoma cell lines. Cell lines were infected with untargeted virus alone or in 
conjunction with a biphasic adapter targeted to CD40 (sCAR-CD40L) or a nega-
tive control (sCAR-6his). The use of the targeted adapter increased transduction 
in both cell lines and this was reduced to background levels with sCAR-6his. The 
values were shown as relative infectivity by taking the level in untargeted virus 
as 100% and expressing other readings as relative percentage change. error 
bars indicate standard deviation. ***p < 0.001.
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Integrin analysis of cell lines. The cellular uptake of Ad is a 
multi-step process requiring viral binding to a cell surface recep-
tor followed by interaction with surface integrins which mediate 
internalization of the virus.8,10,15,27 Since there are differences in 





integrin in adenoviral infection of canine lymphoma cells was 
evaluated. The canine lymphoma cell lines OSW and 17–71 were 




 integrin levels to determine if 
differential expression might help explain the disparities in trans-
duction activity demonstrated between these cell lines (Fig. 6). 




 approximately 10-fold 
above background; however, expression was much lower on 17–71 
cells (approximately 2-fold). Primary lymphoma cell lines also 









 integrin appear to be an obstacle to efficient 
adenoviral infection of canine lymphoma cells.
Discussion
A major advance in the design of Ad vectors to treat tumors was 
the development of methods to selectively transduce target cells 
in a CAR-independent manner. This approach also circumvents 
the lack of native CAR receptors on the surface of many tumor 
cells, coupled with the need to de-target Ad from normal cells 
that are susceptible to infection due to the presence of CAR.6,7,11 
The results of the above experiments confirm most primary 
canine B-cell lymphomas and many primary T-cell lymphomas 
express high levels of CD40 on their surface making this protein 
achieved was with the use of the bispecific adapter plus wt virus 
(Fig. 5). In dog 1, the use of the bispecific adapter with untar-
geted virus increased luciferase activity by 200-fold when com-
pared to untargeted virus alone. While there was an increase in 
transduction with the recombinant vectors Ad5-ff-hCD40L and 
Ad5-ff-cCD40L compared to untargeted vectors (1.8- and 7-fold, 
respectively), this was less dramatic. The level of transduction 
with Ad5-ff-cCD40L was comparable to that observed in control 
cells. In dog 2, transduction increased 54-fold with the bispecific 
adapter plus untargeted virus, however, while transduction was 
observed with the targeted viruses, it was less than that observed 
with the wt virus and approximately 100-fold less than in control 
cells in the case of Ad5-ff-hCD40L and 10-fold less with ad5-
ff-cCD40L. In dog 3, transduction was increased 4-fold with 
the use of the bispecific adapter over wt alone, and again there 
was very low luciferase activity in response to transduction with 
Ad5-ff-hCD40L and none with Ad5-ff-cCD40L. Interestingly, 
in both dogs 1 and 2, transduction was higher with the canine 
CD40 targeted virus than with human sequence, which was an 
effect opposite to that observed in control cells. Overall, this 
data is consistent with that observed in OSW cells where trans-
duction via the sCAR-CD40L adapter was more efficient than 
retargeted viruses and retargeted Ad were much less efficient than 
hypothesized.
The limited levels of transduction by CD40 targeted virus 
observed in both primary canine lymphoma cells and canine lym-
phoma cell lines raises the potential for an absent component or 
inoperative step in the viral entry pathway.
Figure 4. CD21 and CD40 expression by primary canine lymphoma cells. Cells extracted from lymph nodes of canine patients diagnosed with lym-
phoma where transduction was attempted with retargeted vectors. Cells were stained with anti-CD40 antibody labeled with Zenon Alexa 610/Rpe 
and antiCD21 antibody labeled with Zenon Alexa 660. Top panel shows CD40, lower panel CD21.
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 integrins in neoplastic B lymphocytes can 
be upregulated following engagement of CD40 with its ligand. 
This interaction leads to a five-fold increase in Ad-mediated gene 
transfer in these cells.29 Additionally, B-lymphocyte proliferation 
has been demonstrated following CD40-CD40L interaction in 
the presence of IL-4.31,32 As the experiments were conducted in 
cells extracted from lymph nodes and were not enriched for B 
lymphocytes, the combination of the CD40-CD40L engagement 
in this multi-cellular environment, with the potential release of 
endogenous growth factors, may have contributed to the upregu-
lation of cell surface proteins necessary for viral internalization. 
Although lymphoma cells have low levels of surface CAR, inter-
action with other receptors, including the α2 domain of MHC 
class I molecules, have been implicated with virus binding,33 
which may also indicate an increased ability of cells to internal-
ize Ad. Based on these studies, the retargeting of adenovirus to 
selectively transduce lymphoma cells will require overcoming 
the inability of these cells to internalize Ad based on a paucity 
of cell surface integrins. Interestingly, in the above experiments, 
the bispecific sCAR adapter was found to be the most effective 
method of achieving transduction in both lymphoma cell lines 
and primary cells. The mechanism by which this is achieved 
needs to be examined further and could be important in design-
ing a targeted therapy for B-cell lymphoma.
Methods
Cells lines and primary cells. HEK293 and DH82 (canine his-
tiocytic cell line) cells were purchased from ATCC and grown 
in DMEM/F12 supplemented with 10% fetal bovine serum 
(FBS) (Hyclone), 1% antibiotic/antimycotic solution contain-
ing penicillin, streptomycin and amphotericin (Cellgro), and 
grown at 37°C in 5% CO
2
. 293CD40 cells were created by stable 
transfection of HEK293 cells with a linearized plasmid express-
ing full-length canine CD40 cDNA. HEK293 cells were stably 
attractive as a potential molecule for 
retargeted antitumor Ad vectors.
Retargeting of Ad has been 
demonstrated using a number of 
approaches, including genetic modi-
fication of the fiber knob or the use 
of bispecific adapters to redirect the 
virus.28 In the experiments described 
herein, successful retargeting of 
Ad to CD40 using CD40L in the 
293cCD40 cell line with capsid-
modified virus was demonstrated. 
However, CD40-positive lymphoma 
cell lines and CD40-positive pri-
mary lymphomas proved generally 
resistant to transduction by modi-
fied Ad, with both OSW and 17–71 
cells showing no luciferase activity 
in response to infection with either 
Ad5-ff-hCD40L or Ad5-ff-cCD40L 
at a range of MOIs. No luciferase 
activity was present in the majority of primary lymphoma cells 
infected, with only one case showing moderate luciferase expres-
sion following infection with Ad5-ff-cCD40L. The use of an 
sCAR-CD40L bispecific adapter complexed with wt Ad5 was 
more efficient at transducing cells in the OSW cell li e and two 
of the primary canine cell cultures.
As canine B-cell lymphoma cells, proven to express adequate 
levels of CD40, are refractory to infection with CD40 targeted 
Ad vectors, the failure of infection must be due to some mecha-
nism occurring after initial binding of the virus to the cell surface. 
Potential points of infection failure may include virus internaliza-
tion, un-coating, and/or nuclear trafficking. Virus internaliza-





 integrins,27 which may not be present 
on some tumors. Human neoplastic B lymphocytes have been 









Additionally, previous work has suggested that lack of integrin 
seems to be a crucial barrier to transducing B-lymphocyte cell 




 integrin on canine lymphoma cells 
was evaluated in this study, the lack of an available reagent pre-









 integrin expression on the OSW 
and 17–71 cell lines correlated with the transduction efficiency 
of wt virus, alone and in conjunction with a bispecific adapter, in 





 integrin may play a role inensuring internalization of the 
virus.
Our bispecific adapter molecule was partially successful trans-
ducing both cell lines and primary neoplastic cells. In fact, the 
highest level of luciferase activity detected was in two of the 
primary cell assays that had not been cryopreserved and were 
infected with wt Ad and the bispecific adapter sCARCD40L. 
This may indicate that either the modified viruses are not as effi-
cient as wt at transducing cells, or the use of the bispecific adapter 
is responsible for this increased transduction. Previous research 
Figure 5. CD40-targeted transduction in primary cells. Three primary cultures of cells obtained from 
lymph nodes of lymphoma-affected dogs were infected within 24 h of collection with untargeted virus 
alone (control), untargeted virus and sCAR-CD40L, Ad5-ff-hDC40L or Ad5-ff-cCD40L and luciferase 
activity was measured from cell lysates. The values were shown as relative infectivity by taking the 
level of luciferase expression of Ad5 transduced cells as 100% and expressing other readings as relative 
percentage change. error bars indicate standard deviation. ***p < 0.001.
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in complete media and incubated at 37°C prior to infection or 
analysis by flow cytometry or cryopreserved by re-suspending at 
1 x 107 cells/ml in Gibco Recovery Cell Culture Freezing Media 
(Invitrogen).
Flow cytometry. The following antibodies were used to detect 
cell surface expression of receptors: rat anti-canine CD4-FITC 
(clone YKIX302.9, AbD Serotec, Oxford UK), rat anti-canine 
CD8-PE (clone YCATE55.9, AbD Serotec), mouse anti-canine 
CD21 (Clone CA2.1D6, AbD Serotec) labeled with Zenon anti-
mouse Alexa Fluor 610/R-PE (Invitrogen), mouse anti-human 
CD40 antibody (Clone B-B20, Diaclone Bensancon, France) 





 (Clone MAB1976, Millipore, Bellerica, 
MA) conjugated to PE or labeled with Zenon anti-mouse Alexa 
Fluor 700, and monoclonal antibody to human CAR RmcB (pro-
duced using a hybridoma purchased from ATCC and kindly pro-
vided by Joanne Douglas, University of Alabama, Birmingham, 
AL). Cells were suspended (1 x 106) in 100 μl of staining buffer 
(SB: PBS, 1% BSA, 0.1% sodium azide) and incubated for 20–30 
min on ice. Antibodies were then added and cells incubated on 
ice for 40–60 min in the dark. Following this incubation, cells 
were washed two times in 2 ml PBS, and secondary antibod-
ies were added at this stage if needed, followed by 40–60 min 
incubation and 2x PBS wash. Cells were then re-suspended in 
500 μl flow wash buffer (PBS, 0.1% BSA) and filtered to 50 μm 
prior to analysis. All flow cytometry assays were performed on a 
MoFlo Flow Cytometer and Cell Sorter (Beckman Coulter). The 
transfected with a pcDNA3 vector (Invitrogen, San Diego, CA) 
into which a full-length cDNA amplicon of the canine CD40 
open reading frame had been ligated. Amplicons were confirmed 
for identity and sequence fidelity by direct DNA sequencing 
(Auburn University DNA Sequencing Core) prior to ligation. 
Plasmids were linearized outside the CD40 and Neo coding and 
control regions prior to transfection and then transfected and 
clones were selected in G418 media as previously described in 
reference 18.
The OSW canine lymphoma cell line was provided by Dr. 
William C. Kisseberth, The Ohio State University, and the 
17–71 cell line was provided by Dr. Steven Suter, North Carolina 
State University, and have been previously described in reference 
19 and 20. These cell lines were grown in RPMI supplemented 
with 10% FBS, 2 mM L-glutamine and 1% antibiotic/antimy-
cotic solution and maintained at 37°C and 5% CO
2
.
Primary lymphoma cells were obtained by mechanical dis-
ruption of tissue obtained following excision of lymph nodes 
surgically removed from untreated canine lymphoma patients 
and submitted for histologic analysis as part of standard medi-
cal care. Briefly, lymph node tissue was placed in a sterile 6 cm 
dish, with enough complete media (RPMI with 10% FBS, 2 mM 
Glutamax, 1% antibiotic/antimycotic solution) to cover the tis-
sue and cut into sections approximately 25 mm2. These pieces 
were then passed through a sterile 70 μm nylon filter. Media 
was added to a total of approximately 10 ml and the cells were 
centrifuged at 250x g for 5 min. Cells were either re-suspended 
Figure 6. expression of αvβ3 receptors on lymphoma cell lines and primary cells. staining of αvβ3 receptors on OsW and17-71 cell lines and two of the 
primary lymphoma cases where transduction was observed.
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2% FBS and 200 μl aliquots were added to cell monolayers. The 
cells were incubated with virus for 1 h at 37°C to allow virus 
internalization after which 300 μl of complete media was added 
to each well. Between 24 and 72 h post infection, cells were col-
lected, lysed and luciferase activity measured using the Luciferase 
Assay System (Promega, Madison, WI) following the manufac-
turer’s directions. To determine efficiency of Ad-mediated transfer 
using an sCAR-CD40L or sCAR-His
6
 biphasic adapter, aliquots 
of Ad5CMVLuc were mixed with 20–100 μg of the biphasic 
adapter and incubated at room temperature for 30 min. The virus-
sCAR complexes were diluted with media supplemented with 2% 
FBS and infection proceeded as described above. Blocking assays 
with soluble Ad5 knob were conducted by diluting the soluble 
knob to 100 μg in 200 μl cold media followed by addition to each 
well. Cells were then incubated on ice for 1 h, recombinant knob 
removed, washed and infected with the appropriate virus dilution 
as described above. All experiments were conducted in triplicate 
and repeated at least two times.
Acknowledgements
This work was supported by NIH grant 5R01CA113454-04. The 
authors thank Allison Church Bird for flow cytomety assistance 
and Maninder Sandey for statistical analysis.
expression profiles were determined using Summit 4.3 software 
(Beckman Coulter).
Adenovirus constructs. Luciferase-expressing vectors encod-
ing artificial fiber proteins containing human (Ad5-ff-hCD40L) 
or canine (Ad5-ff-cCD40L) CD40L were constructed as previ-
ously described in reference 21. Luciferase-expressing Ad5 vectors 
encoding the native fiber protein were constructed as previously 
described in reference 22 and 23.
All Ad5 vectors were isolated from infected HEK293 cells and 
purified by equilibrium centrifugation in CsCl gradients accord-
ing to a standard protocol.24 The protein concentrations in the 
viral preparations were determined using the D
C
 protein assay 
(Bio-Rad, Hercules, CA) with purified bovine serum albumin 
(BSA) as a standard. The virus titers were calculated using the 
formula: 1 μg of protein = 4 x 109 viral particles (vp). The fusion 
proteins sCAR-His
6
 and sCAR-CD40L were constructed as pre-
viously described in reference 25.
Gene transfer assays. Transduction by the panel of recombi-
nant Ad5 vectors (Ad5CMV, Ad5-ff-hCD40L, Ad5-ff-cCD40L) 
was examined using luciferase as the reporter gene. Cells were 
grown in triplicate at a density of 1 x 105 cells/well in a 24 well 
plate. Virus dilutions were made in multiplicities of infection 
(moi) ranging from 101–104 vp/cell in media supplemented with 
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